Furthermore, the authors suggested that a background TET2 mutation alters the transcriptional effects of JAK2 and therefore prevents the upregulation of its proliferative program, potentially resulting in a weaker “MPN-phenotype”, which may on its turn explain the decreased sensitivity towards ruxolitinib. Here, TET2 is linked to myeloproliferative neoplasm.